Dr. Kircik discusses a recent FDA-approval of an IL-17 inhibitor that has demonstrated to be safe and effective in patients with psoriasis.
Dr. Del Rosso discusses how to provide the correct treatment for the various presentations of psoriasis along with the impact psoriatic arthritis can have on these patients.
Dr. Gelfand discusses cardiovascular risk in patients with psoriasis and advises how dermatologists should be addressing this risk with their patients through education and regular screening for cardiovascular risk factors.
Dr. Del Rosso discusses ways in which he’s modified his consultation style when speaking to patients with psoriasis who are about to commence treatment with a biologic.
George Martin, MD, discusses the specific role TNF inhibitors play for the treatment of psoriasis along with an important safety implication to be aware of for treating patients during pregnancy.
Dr. Del Rosso discusses biologic options for treating patients with psoriasis and psoriatic arthritis as well as pregnant patients.
Dr. Stein Gold discusses insights from clinical trials on new and upcoming systemic agents for psoriasis, including deucravacitinib and bimekizumab.
George Martin, MD, discusses TNF inhibitors for the treatment of psoriasis and how these classic biologic agents currently fit into the ever-expanding arsenal of drugs for psoriasis.